Viatris Finalizes Pacira BioSciences Purchase at $36.50 Per Share
Viatris expects the acquisition to contribute $90 million to $100 million in total revenue from Nov. 17 through Dec. 31.

Viatris Inc. completed its $36.50-per-share acquisition of Pacira BioSciences, Inc. on Tuesday, adding two non-opioid pain treatments to its U.S. business and forecasting a revenue contribution before year-end.
Viatris expects the acquisition to contribute $90 million to $100 million in total revenue from Nov. 17 through Dec. 31, 2026. The company's Nov. 5 financial guidance did not include a Pacira contribution.
Pacira is now a wholly owned Viatris subsidiary. Peach Purchaser Sub Inc., another wholly owned Viatris subsidiary, accepted about 32.93 million Pacira shares that had been tendered and not withdrawn. Those shares represented 66.46% of the total outstanding. A subsequent merger gave holders of the remaining shares the right to receive $36.50 apiece in cash.
The companies estimated the transaction's equity value at $1.65 billion when they announced their agreement Oct. 8. Pacira brings EXPAREL, a treatment for acute pain after surgery, and ZILRETTA, a treatment for knee pain caused by osteoarthritis. Viatris has positioned both products alongside its fast-acting meloxicam opportunity in its U.S. medicines business.
Viatris previously set an annual cost-savings target above $50 million by the end of 2028. It estimated about $75 million in one-time costs to achieve those savings. Viatris CEO Scott A. Smith said the combination could “accelerate our path to sustained revenue and earnings growth,” though the company cautioned that expected benefits and savings may not materialize.
Pacira shares will be delisted from the Nasdaq Global Select Market.